A Technology Whose Use is Indispensable

Ralf Boehling, senior manager Process Development,  Process Screening/Kinetics...
Ralf Boehling, senior manager Process Development, Process Screening/Kinetics Lab, BASF

The existing market situation has already led to a shift in strategy from large quantity chemicals to highly innovative specialties. For many syntheses you can use classical batch vessel. But if you are handling highly toxic, hazardous substances or the syntheses have to run under high pressure, high temperature or the products are thermally unstable, or the syntheses includes a gas phase step, you preferably have to work under continuous flow conditions. So, for BASF there is a need to open these process windows. But one of the major problems to face is that the process development for a contin­uous plant from lab to production plant is not quick enough and causes high development cost. Additionally, it takes a long time for construction and building the technical plant. Especially for small scale plants the cost is prohibitive if building the plant traditionally on site step by step. This, however, severely increases the investment risk for new products because the market needs and price structures cannot be realistically foreseen. Therefore, to shorten the process development time and to reduce cost and time for building small scale continuous plants is a platitude but of course is the key for new innovative processes, reactors and products.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
19.03.2025 • TopicsStrategy

The Future of Demand for Chemicals

The chemical industry is shifting to sustainability-related products, with demand growing 4.5 times faster than conventional ones. Companies must revise their market strategies to capitalize on this opportunity.

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.